- Home
- GILD vs TXN Comparison
GILD vs TXN Comparison
Compare GILD & TXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | TXN |
|---|---|---|
| Founded | 1987 | 1930 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.9B | 160.9B |
| IPO Year | 1992 | N/A |
Fundamental Metrics
Financial Performance| Metric | GILD | TXN |
|---|---|---|
| Price | $154.98 | $226.27 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 24 |
| Target Price | $141.56 | ★ $216.04 |
| AVG Volume (30 Days) | 8.8M | ★ 9.9M |
| Earning Date | 02-10-2026 | 01-27-2026 |
| Dividend Yield | 2.12% | ★ 2.51% |
| EPS Growth | ★ 1684.21 | 4.81 |
| EPS | ★ 6.78 | 5.45 |
| Revenue | ★ $29,443,000,000.00 | $17,682,000,000.00 |
| Revenue This Year | $4.68 | $11.45 |
| Revenue Next Year | $5.11 | $10.05 |
| P/E Ratio | ★ $22.86 | $41.50 |
| Revenue Growth | 2.40 | ★ 13.05 |
| 52 Week Low | $93.37 | $139.95 |
| 52 Week High | $157.29 | $231.32 |
Technical Indicators
Market Signals| Indicator | GILD | TXN |
|---|---|---|
| Relative Strength Index (RSI) | 70.71 | 69.59 |
| Support Level | $147.00 | $216.13 |
| Resistance Level | $157.29 | $231.32 |
| Average True Range (ATR) | 4.28 | 6.96 |
| MACD | 0.86 | 0.07 |
| Stochastic Oscillator | 88.30 | 86.34 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About TXN Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.